List of Excipients in API cholestyramine for oral suspension
✉ Email this page to a colleague
Excipients in ANDA-approved (generic) drugs containing cholestyramine for oral suspension
Detailed excipient profiles for cholestyramine for oral suspension
Excipient focus: AMMONIUM GLYCYRRHIZATE
cholestyramine for oral suspension drug variants containing AMMONIUM GLYCYRRHIZATE
| Company | Ingredient | NDC |
|---|---|---|
| Chartwell RX LLC | cholestyramine for oral suspension | 62135-008 |
| >Company | >Ingredient | >NDC |
cholestyramine for oral suspension drug variants not containing AMMONIUM GLYCYRRHIZATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: ANHYDROUS CITRIC ACID
cholestyramine for oral suspension drug variants containing ANHYDROUS CITRIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| Chartwell RX LLC | cholestyramine for oral suspension | 62135-008 |
| >Company | >Ingredient | >NDC |
cholestyramine for oral suspension drug variants not containing ANHYDROUS CITRIC ACID
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: D&C RED NO. 30
cholestyramine for oral suspension drug variants containing D&C RED NO. 30
| Company | Ingredient | NDC |
|---|---|---|
| Chartwell RX LLC | cholestyramine for oral suspension | 62135-008 |
| >Company | >Ingredient | >NDC |
cholestyramine for oral suspension drug variants not containing D&C RED NO. 30
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: FRUCTOSE
cholestyramine for oral suspension drug variants containing FRUCTOSE
| Company | Ingredient | NDC |
|---|---|---|
| Chartwell RX LLC | cholestyramine for oral suspension | 62135-008 |
| >Company | >Ingredient | >NDC |
cholestyramine for oral suspension drug variants not containing FRUCTOSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: PECTIN
cholestyramine for oral suspension drug variants containing PECTIN
| Company | Ingredient | NDC |
|---|---|---|
| Chartwell RX LLC | cholestyramine for oral suspension | 62135-008 |
| >Company | >Ingredient | >NDC |
cholestyramine for oral suspension drug variants not containing PECTIN
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: PROPYLENE GLYCOL ALGINATE
cholestyramine for oral suspension drug variants containing PROPYLENE GLYCOL ALGINATE
| Company | Ingredient | NDC |
|---|---|---|
| Chartwell RX LLC | cholestyramine for oral suspension | 62135-008 |
| >Company | >Ingredient | >NDC |
cholestyramine for oral suspension drug variants not containing PROPYLENE GLYCOL ALGINATE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SORBITOL
cholestyramine for oral suspension drug variants containing SORBITOL
| Company | Ingredient | NDC |
|---|---|---|
| Chartwell RX LLC | cholestyramine for oral suspension | 62135-008 |
| >Company | >Ingredient | >NDC |
cholestyramine for oral suspension drug variants not containing SORBITOL
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: SUCROSE
cholestyramine for oral suspension drug variants containing SUCROSE
| Company | Ingredient | NDC |
|---|---|---|
| Chartwell RX LLC | cholestyramine for oral suspension | 62135-008 |
| >Company | >Ingredient | >NDC |
cholestyramine for oral suspension drug variants not containing SUCROSE
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Excipient focus: XANTHAN GUM
cholestyramine for oral suspension drug variants containing XANTHAN GUM
| Company | Ingredient | NDC |
|---|---|---|
| Chartwell RX LLC | cholestyramine for oral suspension | 62135-008 |
| >Company | >Ingredient | >NDC |
cholestyramine for oral suspension drug variants not containing XANTHAN GUM
| Company | Ingredient | NDC |
|---|---|---|
| >Company | >Ingredient | >NDC |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Generic Entry Opportunies 2025 - 2026
NCE-1 Patent Challenge Dates 2025 - 2026
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2025, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch